(10 beds). Baseline nosocomial infection surveillance was performed during April and May of 1999.
Hospital C is a private, 180-bed hospital situated in the city of Buenos Aires, Argentina, with one MS-ICU (10 beds). Baseline nosocomial infection surveillance was performed during September and October of 2000.
Each ICU provides tertiary care to patients with a wide range of medical and surgical issues, including cardiac bypass operation, and neurosurgical and orthopedic procedures.
Surveillance
Standard Centers for Disease Control and Prevention (CDC) National Nosocomial Infections Surveillance (NNIS) definitions for nosocomial infections were used. 8 Surgical site infections were excluded. We performed active prospective surveillance for nosocomial infections in the MS-ICUs. The data collected on each infection included the date; infection site; patient demographic information; and ventilator, central venous catheter, and urinary catheter use.
The overall rate of patients with nosocomial infection (percent) was calculated by dividing the total number of patients with nosocomial infections by the total number of patients in the ICU. The nosocomial infection incidence density rate was calculated by dividing the total number of nosocomial infections by the total patient-days. For pneumonia, bloodstream infection (BSI), and urinary tract infection (UTI), device-associated infection rates were calculated by dividing the number of device-associated infections by the total number of appropriate device-days.
Statistical methods
Data was abstracted from standard forms, and analyzed using Epi info software (v. 6.04b, CDC, Atlanta, Ga). Attributable mortality was calculated by comparing mortality in patients with >7 days of hospital stay with and without nosocomial infection (ventilatorassociated pneumonia [VAP] , catheter-associated [CA] BSI, CA UTI). 9 Excess length of stay was calculated by subtracting the average length of stay for patients without nosocomial infection from the average length of stay of patients with nosocomial infection, matching for length of stay >7 days.
RESULTS
For 6 months in the years of 1998, 1999, and 2000, we collected data on 57 patients with 128 nosocomial infections among 213 patients discharged from the hospital for a total of 1422 patient-days in 3 ICUs for adult patients. The overall nosocomial infection rate was 27% and 90 per 1000 patient-days as shown in Table 1 .
A total of 102 (80%) nosocomial infections were device-related, including VAP, catheter-related (CR) BSI, and CA UTI. Site-specific infections are shown in Table  2 . The most frequent site of infection was CR BSI accounting for 32% of all nosocomial infections, followed by VAP (25%), and CA UTI (23%). Nosocomial infections not associated with devices included pneumonia, accounting for 11% of infections. The remainder of the nosocomial infections were peripheral lineassociated phlebitis, sepsis, and BSI (9%).
When infection rates were calculated by using device-days as the denominator, the rate of CR BSI was 44.61 per 1000 line-days; the rate of VAP was 51 per 1000 ventilator-days; and the rate of CA UTI was 23 per 1000 catheter-days. This is shown in Table 3 .
Attributable mortality was highest for VAP (34%), followed by CR BSI (25%) and CA UTI (5.7%). The excess length of stay was 13 days for CR BSI, 10 days for VAP, and 5 days for CA UTI, as shown in Table 4 .
DISCUSSION
Nosocomial infections are associated with high morbidity, mortality, and hospital costs. A key aspect of nosocomial infections control is surveillance, as shown by the Study on the Efficacy of Nosocomial Infection Control Programs, which reported that surveillance combined with an infection control program reduces noscomial infections by approximately 30%. 10 We found high overall rates of nosocomial infection in our 3 ICUs, ranging from 18% to 54%. When compared with reports from other Latin American countries, our rates are comparable with those reported in Rio de Janeiro, Brazil 11 ; however, other developing countries have found lower rates: Khuri-Bulos et al 12 reported an overall rate of nosocomial infection of 17% in the MS-ICU of Jordan University Hospital (Amman, Jordan).
In the United States, nosocomial rates in medical ICUs range from 7.7% to 24%. 13, 14 Wallace et al 15 reported rates of 11.64% in a trauma ICU and 6.4% in a surgical ICU.
Our study found CR BSI to be the most frequent nosocomial infection. This is in contrast to other studies, in the United States and Europe, where CR BSI has been reported to be the third most common site of infection. 13, 16 We used the CDC definition of CR BSI, which is also used in the European Prevalence of Infection study and NNIS surveillance in the United States. Possible reasons for our high rates include lack of maximal barrier precautions at line insertion and site care postline insertion. Implementation of standard infection control practices, including attention to strict asepsis and site care, would greatly decrease the rate of CR BSI in Argentina.
In our study, we report an attributable mortality of 25% with CR BSI. Data on the attributable mortality of CR BSI is conflicting, ranging from 12% to 35% in some prospective studies. 17, 18 Other studies have, however, failed to show an attributable mortality with CR BSI. In a small, matched case control study of 49 patients with CR BSI, Rello et al 19 failed to show a difference in mortality as a result of CR BSI. A recent prospective cohort study that matched cases and controls on age, gender, Simplified Acute Physiologic score (SAPS) II, and duration of intravenous catheterization also did not find a statistically significant difference in CR BSI attributable mortality. 20 Numerous studies have reported an increased length of stay with CR BSI. 18, 20 We found 13 extra days of hospitalization attributable to CR BSI; this is lower than that reported by Pittet et al 18 (24 days) in their study conducted in a surgical ICU.
Most studies have found VAP to be the most frequent nosocomial infection, accounting for 17% to 47% of ICU infections. 16, 21 In a study of 135 patients in a MS-ICU, Bercault and Boulain 23 found a high attributable mortality with VAP and prolonged hospital stay attributable to VAP. 22 Heyland at al 23 reported similar results in a study of 177 patients in the ICU. VAP accounted for 25% of the nosocomial infections in our study and was associated with 10 extra days of hospital stay and an attributable mortality of 34%. Possible explanations for our high rate of VAP include lack of attention to head of bed elevation, presence of condensate in circuit, lack of high-efficiency filters, and high patient-torespiratory staff ratio, leading to infrequent suctioning.
CA UTI is associated with a 3-fold increase in mortality, and increased hospital costs and considerable morbidity. 24 In our study, we found that CA UTI was associated with a 5% attributable mortality and 5 extra days of hospital stay. This is in contrast to a study by Bryan and Reynolds, 25 who analyzed 1520 episodes of hospital-acquired bacteremia in South Carolina; 221 episodes were attributable to the urinary tract and 30% of patients with urinary tract-related bacteremia died with an estimated 12.7% attributable mortality of CA UTI. Implementation of measures proven to decrease the risk of CR bacteriuria, such as closed drainage systems and limiting the duration of urinary catheterization to the minimum number of days possible, is necessary to prevent CA UTI.
Data from the European Prevalence of Infection Study, on the basis of 10,038 patients in 1417 ICUs, showed that the most common sites of infection were pneumonia (47%), urinary tract (18%), and bloodstream (12%). 16 In a study of 505 patients in a neurologic ICU, Dettenkofer et al 26 reported a 24.2% overall rate of nosocomial infection; site specific infection rates were 20.4 pneumonias per 1000 ventilator-days, 10 UTIs per 1000 catheter-days, and 1.9 central line-associated BSIs. A lower overall rate of nosocomial infection (11.2%) has been reported by Laborde et al 27 in their neurosurgical ICU; however the rate increased to 36% with prolonged ICU stay. In our study, the majority of infections at the 3 most common sites (bloodstream, respiratory, and urinary tract) were associated with devices, emphasizing the impact of device use on the development of ICU infections.
We limited our surveillance to MS-ICUs in similar hospitals to limit confounding of nosocomial infection rates by different types of ICU, where device use and length of stay may vary considerably resulting in differing nosocomial infection rates. Limitations noted previously regarding the use of NNIS definitions also apply to our study 13 ; overestimation of nosocomial infection rates may have occurred by using the overinclusive NNIS criteria.
When compared with data generated by the NNIS, our rates of CA UTI, CR BSI, and VAP are much higher and above the 90th percentile. NNIS pooled means from 1995 to 2001 for CA UTI, CR BSI, and VAP are 5.8, 5.3, and 10.5 per 1000 device-days, respectively. 28 Differences in infection control practices and lack of established infection control programs may account for our higher rates.
Establishment of multifaceted infection control programs emphasizing focused education, maximal sterile precautions at device insertion, limiting device use to only as necessary, and ongoing surveillance is needed to decrease the burden of nosocomial infection in the ICU. The development of a national program that encompasses all the aspects discussed above and monitors compliance with key aspects of infection control will be instrumental in decreasing the burden of nosocomial infection in Argentina.
CONCLUSION
Nosocomial infections are common in medical ICUs in Argentina, with rates similar to those reported from other Latin American countries. CA BSI is the most frequent site of infection, followed by VAP and UTI. These infections are associated with high attributable mortality and excess length of stay. Ongoing surveillance and infection control efforts are necessary to target areas for intervention to reduce the burden of these nosocomial infections.
